The company’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other ...

Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials ...

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Mural Oncology in a research ...

Mural Oncology (NASDAQ:MURA – Get Free Report) was downgraded by stock analysts at Raymond James from a “strong-buy” rating ...

H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Mural Oncology (MURA) to $6 from $18 and keeps a Buy rating on the ...

Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis Continued demonstration of favorable tolerability ...

A Waltham company pulled the plug on a Phase 3 cancer trial, while a different Waltham company continued its leadership ...

The City of Indio is honoring the life and legacy of Desirae "Desi" Ava Grace Cechin with two murals on Civic Center Drive.